The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005/CRIMSON).
 
Go Saito
Honoraria - AstraZeneca Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuko Oya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly
Consulting or Advisory Role - Lilly
 
Yoshihiko Taniguchi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Mundipharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan; Ono Pharmaceutical
 
Hayato Kawachi
Honoraria - AstraZeneca Japan; Chugai Pharma Europe; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Boehringer Ingelheim; Lilly; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; Chugai Pharma
 
Hirotaka Matsumoto
Honoraria - AstraZeneca Japan; Taiho Pharmaceutical
 
Shunichiro Iwasawa
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Hidekazu Suzuki
Honoraria - AstraZeneca Japan; Chugai Pharma; Ono Pharmaceutical
 
Takayuki Niitsu
No Relationships to Disclose
 
Eisaku Miyauchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma
Research Funding - Boehringer Ingelheim; Chugai Pharma (Inst); Lilly (Inst)
 
Takashi Yokoi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
 
Miho Mitsui
No Relationships to Disclose
 
Takeshi Uenami
Honoraria - AstraZeneca; Chugai Pharma
 
Yoshihiko Sakata
Honoraria - AstraZeneca Japan
 
Daisuke Arai
No Relationships to Disclose
 
Asuka Okada
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD
 
Satoshi Hara
No Relationships to Disclose
 
Shunsuke Teraoka
Honoraria - AstraZeneca Japan; Chugai Pharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
 
Masaki Kokubo
Honoraria - AstraZeneca Japan